Shots:
- The US FDA has approved Datroway (datopotamab deruxtecan-dlnk; 6 mg/kg) for adults with locally advanced or metastatic EGFR-mutated NSCLC previously treated with EGFR therapy & Pt CT
- Approval was based on the global P-II (TROPION-Lung05) trial results (n=137) and supported by data from the P-III (TROPION-Lung01) trial (n=590), which showed a 45% confirmed ORR (n=114) with previously treated locally advanced or metastatic EGFR-mutated NSCLC, with 4.4% complete and 40% partial responses. mDoR was 6.5 mos.
- Daiichi Sankyo & AstraZeneca are testing Datroway alone or with osimertinib in advanced EGFR-mutated NSCLC in the P-III TROPION-Lung14 and Lung15 trials
Ref: Daiichi Sankyo | Image: Daiichi Sankyo| Press Release
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
